Xiaochun Li
Papers
1
Total Citations
42
H-Index
1
About
Xiaochun Li is a pioneering researcher whose work bridges oncology, proteomics, and clinical diagnostics. Her key research areas include breast cancer biomarker discovery, plasma proteomics, and the molecular characterization of HER2-positive malignancies. Li’s most notable contribution is the identification of declining plasma fibrinogen alpha fragments as a specific biomarker for HER2-positive breast cancer, a breakthrough detailed in her highly cited 2006 study (42 citations). This work demonstrated that these fragments revert to normal levels after surgical tumor removal, offering a potential blood-based diagnostic tool to complement radiological screening—a critical advance given the lack of simple, noninvasive tests for this aggressive cancer subtype. By employing automated proteomic screening of plasma specimens, Li pioneered methods to detect subtle molecular signatures that distinguish HER2-positive patients from healthy individuals. Her findings have significant implications for early detection, treatment monitoring, and reducing reliance on invasive biopsies. Li’s research exemplifies how translational proteomics can directly impact clinical oncology, and her work continues to inspire efforts toward personalized, blood-based cancer diagnostics.
Research Focus
Key Achievements
Top Papers
- 1